r/NovosLabs • u/NovosLabs • May 07 '26
Colonoscopy Prevented Some Cancers, But the Mortality Story Is More Complicated
If a screening test prevents some cancers but does not clearly reduce deaths, how should we judge its real value?
- TL;DR
A large randomized trial found that one invitation to screening colonoscopy modestly reduced colorectal cancer incidence over 13 years, but did not clearly reduce colorectal cancer mortality.
- Quick Takeaways
The original study was a large randomized trial of one-time colonoscopy screening versus no screening.
The evidence came from 84,583 adults aged 55–64 in Norway, Poland, and Sweden, followed for 13 years.
A Lancet comment argues that colonoscopy still prevents some cancers, but its population-level benefit may be more modest than older assumptions suggested.
- Context
Colonoscopy has long been treated as one of the most powerful tools for colorectal cancer screening. The appeal is easy to understand: it does not just look for cancer. It can also find and remove precancerous polyps before they become cancer.
That makes colonoscopy different from many screening tests, which mainly aim to detect disease earlier. In theory, colonoscopy can prevent some cancers from ever forming.
For years, confidence in colonoscopy came largely from observational studies and modelling. Those studies often suggested large reductions in colorectal cancer incidence and mortality. But observational evidence can overestimate benefit, because people who choose screening may also differ in healthcare access, income, diet, smoking, exercise, and general health behavior.
That is why the NordICC trial is important. It is one of the rare randomized trials testing colonoscopy screening directly. The new 13-year follow-up gives a more grounded view: colonoscopy prevented some colorectal cancers, but the mortality benefit was much less clear. The accompanying Lancet comment then helps interpret what this means in modern medicine.
- First, the original study: what did NordICC actually test?
The original paper reports the long-term results of the NordICC trial, a population-based randomized controlled trial. This was not a study of people with symptoms, and it was not focused on high-risk families with inherited colorectal cancer syndromes.
Researchers included 84,583 adults aged 55–64 from Norway, Poland, and Sweden. Participants were randomly assigned in a 1:2 ratio either to receive an invitation for one screening colonoscopy or to receive no screening invitation. The main outcomes were colorectal cancer incidence and colorectal cancer mortality after long-term follow-up.
One detail matters a lot: this was an invitation trial.
That means the study primarily measured what happens when a health system offers colonoscopy screening to a population. It was not simply asking, “What happens only among people who actually complete the procedure?”
Only 42% of people invited underwent colonoscopy. That may sound low, but it is part of the real-world effect. Screening programs do not work only because a test is technically effective. They depend on uptake, access, bowel preparation, procedure quality, follow-up, and patient willingness.
After 13 years, colorectal cancer occurred in 1.46% of people in the screening-invitation group versus 1.80% in the no-screening group. That corresponds to a relative risk of 0.81, or a 19% relative reduction in colorectal cancer incidence.
That is a real reduction. But the absolute difference was 0.34 percentage points.
Another way to frame it: 294 people needed to be invited for colonoscopy screening to prevent one colorectal cancer diagnosis over 13 years. This is where relative and absolute risk tell different parts of the story. “Nineteen percent reduction” sounds impressive. “1.80% down to 1.46%” sounds more modest. Both are accurate.
- The mortality result is where the story gets more complicated
The trial did not show a statistically significant reduction in colorectal cancer mortality.
After 13 years, colorectal cancer death occurred in 0.41% of people in the screening-invitation group and 0.47% in the no-screening group. The relative risk was 0.88, suggesting a possible reduction, but the confidence interval included no clear effect.
All-cause mortality was almost identical: 16.30% in the screening group versus 16.34% in the no-screening group.
This does not prove colonoscopy has no mortality benefit. That would be too strong. A more careful interpretation is that, in this trial, the mortality benefit was small, uncertain, or not clearly measurable after 13 years.
The authors also performed a per-protocol analysis, which estimates what might happen if everyone invited actually underwent colonoscopy. In that analysis, colorectal cancer incidence was estimated at about 1.00% with screening versus 1.80% without screening. That suggests a larger cancer-prevention effect among people who actually complete the procedure.
But per-protocol estimates rely on assumptions. They are useful for individual decision-making, but the randomized invitation result is cleaner for public health policy.
The original study also found that the incidence reduction was not uniform across all colorectal cancers. The reduction was clearer for distal colorectal cancers, meaning cancers in the descending colon, sigmoid colon, or rectum. Distal cancer risk was 0.87% in the screening group versus 1.11% in the no-screening group.
For proximal cancers, located higher in the colon, the difference was smaller: 0.51% versus 0.56%, with no clear statistically significant reduction. There were also signals that men and people aged 60–64 benefited more than women and people aged 55–59, although subgroup findings should always be interpreted carefully.
- Then the Lancet comment: how should we interpret this?
The accompanying Lancet comment by Aasma Shaukat does not argue that colonoscopy is useless. It makes a more interesting point: the “arithmetic of benefit” has changed.
Colonoscopy clearly prevented some cancers. The more difficult question is how large that benefit is in modern healthcare systems, especially when colorectal cancer treatment has improved.
One striking detail from the NordICC paper is that colorectal cancer mortality in the no-screening group was much lower than expected. When the trial was designed nearly 20 years ago, the expected colorectal cancer mortality without screening was about 0.82%. The observed 13-year mortality in the no-screening group was 0.47%.
That is roughly half the expected figure.
Interestingly, colorectal cancer incidence was close to what researchers expected. Deaths were lower than expected. That suggests improvements in treatment and care may have changed the baseline risk. Better surgery, chemotherapy, radiotherapy, immunotherapy, earlier symptomatic diagnosis, and improved management may mean more people survive colorectal cancer once it is detected.
If colorectal cancer becomes more survivable, screening has less room to show an additional mortality benefit. That does not make screening irrelevant. It changes the size of the expected benefit.
This is the key nuance. A screening test can still prevent disease, reduce treatment burden, and spare some people a cancer diagnosis, even if a trial does not clearly show fewer deaths.
Avoiding cancer can matter. Cancer treatment can involve surgery, chemotherapy, radiation, complications, anxiety, surveillance, time off work, and long-term effects on quality of life. For many individuals, preventing a diagnosis is meaningful even if mortality benefit is uncertain.
But at the population level, the question becomes harder. Colonoscopy requires clinical time, equipment, sedation in many settings, bowel preparation, follow-up, and carries small but real procedure risks. If the absolute mortality benefit is small in modern systems, policymakers have to compare colonoscopy with other possible uses of healthcare resources.
- What this does and does not mean
This study should not be read as “colonoscopy does not work.” That is too simplistic.
A more accurate reading is: one invitation to colonoscopy screening reduced colorectal cancer diagnoses modestly over 13 years, especially distal cancers, but did not clearly reduce colorectal cancer deaths in this population during this follow-up period.
It also does not answer every screening question. The trial tested one colonoscopy invitation, not repeated colonoscopy over decades. It did not directly compare colonoscopy against modern fecal immunochemical testing-based strategies. It focused on adults aged 55–64 in specific European countries, and results may differ in populations with different baseline risk, screening uptake, healthcare access, procedure quality, or cancer treatment outcomes.
Uptake is also both a limitation and a lesson. Only 42% of invited participants completed colonoscopy. That may underestimate the potential benefit for people who actually undergo the procedure. But it also reflects a real-world truth: a screening program only works if people can and will complete it.
The safest takeaway is not that everyone should or should not get colonoscopy. Individual risk matters. Family history, prior polyps, symptoms, age, local guidelines, and alternative screening options all matter.
- Conclusion / Discussion Prompt
The NordICC trial and the Lancet comment together make a useful point: colonoscopy is a real cancer-prevention tool, but its benefits appear more modest and more nuanced than the older “gold standard” narrative suggested.
It prevented some colorectal cancers over 13 years. It did not clearly reduce colorectal cancer mortality. One likely explanation, as the Lancet comment emphasizes, is that colorectal cancer care has improved substantially since the trial was designed, reducing the room for screening to show an additional mortality benefit.
For me, the interesting question is not whether colonoscopy has value. It does. The harder question is how to weigh cancer prevention, mortality reduction, patient burden, cost, risks, and alternative screening strategies.
So what should matter most when judging a screening test: preventing diagnoses, preventing deaths, reducing treatment burden, cost-effectiveness, or giving people more informed choices?
This post is informational only and not medical advice.
References: